Mankind Pharma Ltd

ESG rating update

• ESG rating of 71 assigned to Mankind Pharma for FY26 by NSE Sustainability.
• Rating is independent; the company did not engage NSE Sustainability for the rating.
• Based on publicly available information; disclosed on the company's website.
• Date of disclosure: Oct 15, 2026; no stated material impact.

Target and deal

• Armed Cell Therapeutics B.V. is Belgium-incorporated biotech developing CAR-T therapies.
• Acquisition of 70% stake in ACTx via Mankind Netherlands for EUR 48 million.
• Investment into Mankind Netherlands is a related party transaction.
• ACTx is Belgium-based, developing next-generation CAR-T therapies for cancer.

Deal economics

• Cash consideration of EUR 48 million for 70% ACTx stake.
• Total investment into Mankind Netherlands up to EUR 50 million.
• ACTx investment not a related party transaction.
• EUR 48 million to be invested in ACTx in installments.

Regulatory & timeline

• Regulatory approvals as required by host country.
• Completion timeline per definitive agreement.

Background and scope

• ACTx pipeline includes non-Hodgkin lymphoma and small cell lung cancer.
• Mankind Netherlands established Aug 13, 2026; wholly owned subsidiary.
• ACTx turnover nil; R&D led in US/EU.

Auditor resignation amid liquidation

• S.R. Batliboi & Co. LLP resigned as statutory auditors of Bharat Serums and Vaccines Limited.
• Resignation effective September 28, 2026, due to initiation of voluntary liquidation of BSV.
• Liquidation follows shareholders' September 7, 2026 resolution under IBC and VLP regulations.
• Auditors completed the year-end audit for March 31, 2026; report dated May 12, 2026.
• Regulatory requirement prohibits engagement of auditors during liquidation, prompting their immediate resignation.
• BSV is a material wholly owned subsidiary of Mankind Pharma Limited.

Mankind Pharma Limited — Trading window will be closed with effect from October 01, 2026 till 48 hours after the declaration of unaudited standalone and consolidated financial results of the Company for the quarter and half year ending on September 30, 2026.

Resolution summary

• Purpose: Special resolution to appoint Anish Vanraj Bafna as Non-Executive Independent Director for five years.
• Outcome: Passed; five-year term commencing Aug 10, 2026; total votes 396,204,784; 99.9627% in favour, 0.0373% against.

ESG rating update

• Niche99 ESG Ratings assigns Mankind Pharma 68.21 in Leader category for FY2025-26.
• The company did not engage Niche99; rating prepared independently.
• Niche99 is SEBI-registered Category II ESG rating provider.
• Disclosures available on the company's website.

Meeting Details

• 17 Sep 2026: Jefferies 5th India Forum, Gurgaon; One-on-One / Group Meeting; mode not specified.
• 18 Sep 2026: Health care Forum, Mumbai; One-on-One / Group Meeting; mode not specified.
• 21 Sep 2026: J.P. Morgan India Conference, Mumbai; One-on-One / Group Meeting; mode not specified.

Participants

• Company management/officials to participate in each conference.

Purpose

• Participation in investor conferences for general investor interaction.

Additional Notes

• Meetings subject to change; updated on company website.

BSVL liquidation update

• BSVL, a wholly owned subsidiary, approved voluntary liquidation at EGM Sep 7, 2026, subject to creditors' IBC approval.

Disposal of Broadway subsidiary

• 100% stake in Broadway Hospitality Services Private Limited transferred to AKRK Projects LLP and partners.
• Broadway ceases to be a wholly owned subsidiary with effect from August 31, 2026.

ESG Rating Update

• CRISIL ESG Ratings assigns Mankind Pharma ESG score of 64 in Strong category.
• Core ESG Rating improved to 71 from 60.
• Company states it did not engage CRISIL; report prepared independently using FY2026 disclosures and public data.
• Disclosure available on the Mankind Pharma website.
• No direct financial impact or metrics disclosed.